Climb Bio, Inc.

Item 7.01 Regulation FD Disclosure. On October 23, 2026, Climb Bio, Inc. (the "Company") and Beijing Mabworks Biotech Co., Ltd. ("Mabworks"), issued a press release announcing results for additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-APRIL monoclonal antibody, in development for IgA nephropathy ("IgAN"). These data were presented at the American Society of Nephrology (ASN) Kidney Week 2026, which is taking place October 21-25, 2026, in Denver, Colorado. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit furnished under Item 7.01 of this Current Report on Form 8-K, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing. Item 8.01 Other Events. On October 23, 2026, the Company announced additional data from the Phase 1 clinical development program of CLYM116 in healthy volunteers. CLYM116 was engineered as a pH-dependent "sweeper" antibody intended to facilitate the clearance of a proliferation-inducing ligand ("APRIL") while recycling the antibody, which the Company believes supports deep and durable APRIL suppression with extended dosing intervals. CLYM116 is being evaluated in complementary Phase 1 trials in Australia and China. Both are randomized, double-blind, placebo-controlled, ascending-dose studies designed to evaluate safety, tolerability, pharmacokinetics ("PK"), and pharmacodynamics ("PD") of subcutaneous ("SC") CLYM116 in healthy volunteers and enrolled 46 and 42 participants respectively. The additional data build on previously reported initial Phase 1 results from the trial, with data further supporting the prolonged half-life, deep and durable APRIL suppression, and every-12-week ("Q12W") dosing potential of CLYM116 in IgAN. CLYM116 showed an estimated half-life of approximately 33 days based on the 800 mg dose and 320 mg multiple-ascending dose ("MAD") cohort. PK was consistent across both studies, with linear exposure and no target-mediated drug disposition observed at doses of 160 mg or higher, consistent with sweeper-mediated degradation of APRIL. The additional data also extend the previously reported PD findings. As previously reported, a single 320 mg dose produced greater than 90% suppression of free APRIL and approximately 60-75% suppression of IgA, galactose-deficient IgA1 ("GD-IgA1"), maintained through 12 weeks. In the expanded dataset, a single subcutaneous ("SC") injection of 480 mg or higher produced free APRIL suppression of 90% or more through the full 12-week dosing interval, and a single SC injection of 800 mg, the selected loading dose for the NAVIGATE-2 Phase 2 trial, produced reductions of approximately 70% in Gd-IgA1 and approximately 60% in IgA at 12 weeks. CLYM116 has been generally well tolerated across all dose levels evaluated with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia. Injection site reactions occurred in 5 of 88 participants across both studies, which were all Grade 1 and resolved without intervention. The Company is enrolling patients with IgAN in its ongoing NAVIGATE-2 Phase 2 trial intended to support the Q12W dosing regimen and remains on track to report initial data in the first half of 2027. The Company and Mabworks also expect to initiate a global Phase 3 trial in 2027, pending regulatory feedback. Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" including, without limitation, statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of CLYM116; the anticipated timelines for announcing data from Climb Bio's ongoing and planned clinical trials; the anticipated timelines for enrolling patients in planned clinical trials; the anticipated benefits of Climb Bio's technology transfer and exclusive license agreement with Mabworks; and other statements containing the words "anticipate," "continue," "expect," "may," "plan," "potential," "predict," "project," "target," "will," and similar expressions. Forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its technology transfer and exclusive license agreement with Mabworks; Climb Bio's ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other

Cover Page Interactive Data File (embedded within the Inline XBRL document)